Bullish & Foolish
Full AZTR fundamentals All 466 on the Survival Watch

AZTRAzitra, Inc.

Is Azitra struggling financially?

Yes, by its own account. Azitra told the SEC on 13 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Cries for help

Nothing in the filings we have read reads as a plea for help.

Signs of a way out

  • Regulatory win

    IND clearance from the FDA to commence a Phase 1/2 clinical trial in certain cancer patients undergoing EGFRi targeted therapy. In September 2024, we obtained Fast Track designation by the FDA in this indication.

    Form 10-Q, filed 13 May 2026. Read it on SEC.gov

Sector
Biotech/Pharma
Market cap
$8.0M
Source filing
10-Q 13 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 6months

    If the burn speeds up

    Empty by Dec 2026

  • 9months

    If it eases off

    Empty by Mar 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$6.7M

÷

Cash burned over the last 12 months

$11.2M

What Azitra told the SEC

…no assurance that the Company will be successful in securing additional financing, if needed, to meet its operating needs. These conditions and events create substantial doubt about the ability of the Company to continue as a going concern for twelve months from the date that the financial statements are available to be issued. The financial statements do not include any adjustments that might be necessary should the…

Azitra, Inc., Form 10-Q, filed 13 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 18.2% share-count increase The company issued stock. Each share now owns 15.4% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 41% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt